Compare Heron Therapeutics Inc (HRTX) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs UiPath Inc — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while UiPath Inc trades at $12.01 (market cap $6.30B). The key difference: UiPath Inc is far larger — about 68.9× Heron Therapeutics Inc's market cap, and UiPath Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | PATH | |
|---|---|---|
Market Cap | $91.46M | $6.30B |
Sector | Health | Technology |
52-Week High | $1.96 | $19.29 |
52-Week Low | $0.39 | $9.38 |
Enterprise Value | $189.36M | $5.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
UiPath (PATH) trades at $12.26, up 0.91% today, with a bullish technical outlook and strong support at $12. The company shows improving fundamentals, with revenue growing to $1.43B in 2025 and a projected net profit of $327M in 2026. Recent news highlights AI partnerships and agentic automation growth, though Q1 2026 EPS missed expectations.
Outlook is cautiously optimistic with a consensus price target of $13.33, offering ~9% upside. Key opportunities include high gross margins and AI adoption, while risks involve execution on profitability and competitive pressures. Institutional sentiment is mixed with 25% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
